Neurogene Q1 EPS $(1.00) Misses $(1.14) Estimate, Exits Quarter With Cash & Equivalents Worth $169.5M
Portfolio Pulse from Benzinga Newsdesk
Neurogene reported Q1 EPS of $(1.00), surpassing the analyst consensus estimate of $(1.14) by 12.28%. The company concluded the quarter with $169.5M in cash and equivalents.
May 10, 2024 | 11:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurogene's Q1 earnings per share of $(1.00) exceeded expectations, with a significant cash reserve of $169.5M at quarter's end.
Beating EPS estimates typically generates positive investor sentiment, potentially leading to a short-term stock price increase. The substantial cash reserves further bolster the company's financial stability, making it an attractive investment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100